Table of contents


Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in January 2011 on request of the sponsor.

On 29 November 2007, orphan designation (EU/3/07/512) was granted by the European Commission to MedImmune Oncology, Inc., Netherlands, for 17-(allylamino)-17-demethoxygeldanamycin hydroquinone hydrochloride for the treatment of malignant gastrointestinal stromal tumours.

The sponsorship was transferred to AstraZeneca AB, Sweden, in June 2008 and subsequently to Voising Consulting S.A.R.L., France, in April 2009.

Key facts

Active substance
17-(Allylamino)-17-demethoxygeldanamycin, hydroquinone hydrochloride
Disease / condition
Treatment of malignant gastrointestinal stromal tumours
Date of decision
Orphan decision number

Sponsor's contact details

Voisin Consulting S.A.R.L.
3, rue des Longs Prés
92100 Boulogne
Telephone: +33 1 41 31 83 00
Telefax: +33 1 41 31 83 09

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating